Secrecy and integrity in clinical trials

Journal of Clinical Oncology

Volumn 26, Issue 4, 2008, Pages 680-682

  Wells, Robert J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CONFIDENTIALITY; GOVERNMENT; HEALTH CARE POLICY; MEDICAL RESEARCH; PATIENT CARE; PATIENT SAFETY; PHYSICIAN; PRIORITY JOURNAL; PROFESSIONAL SECRECY; RESPONSIBILITY; SHORT SURVEY; ARTICLE; BREAST TUMOR; ETHICS; FEMALE; HUMAN; INFORMATION DISSEMINATION; MANAGEMENT; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; SOCIAL BEHAVIOR; TREATMENT OUTCOME;

BREAST NEOPLASMS; CONFIDENTIALITY; FEMALE; HUMANS; INFORMATION DISSEMINATION; POLICY MAKING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOCIAL RESPONSIBILITY; TREATMENT OUTCOME;

EID: 39149119996     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.5234     Document Type: Short Survey

References (13)

1. Smith MA, Ungerleider RS, Korn EL, et al: Role of the independent data monitoring committee in randomized clinical trials sponsored by the National Cancer Institute. J Clin Oncol 15:2736-2743, 1998
2. Topol EJ, Blumenthal D: Physicians and the investment industry. JAMA 293:2654-2657, 2005
3. Steinbrook R: Wall Street and clinical trials. N Engl J Med 353:1091-1093, 2005
4. American Society of Clinical Oncology: Interactions with the investment industry: Practical and ethical implications. J Clin Oncol 25:338-340, 2007
5. Whittington CJ, Kendall T, Fonagy P, et al: Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet 363:1341-1345, 2004
6. OPRR Reports Protection of Human Subjects Title 45 Code of Federal Regulations part 46, Department of Health and Human Services. March 15, 1994
7. Ellingberg SS, Fleming TR, DeMets DL: Confidentiality issues relating to the data monitoring committee, in: Data Monitoring Committees in Clinical Trials: A Practical Perspective. John Wiley & Sons, Chicester, England, 2003, pp 69-87
8. Ellingberg SS, Fleming TR, DeMets DL: Statistical, philosophical and ethical issues in data monitoring, in: Data Monitoring Committees in Clinical Trials: A Practical Perspective. John Wiley & Sons, Chicester, England, 2003, pp 119-152
9. Jansen AR, Veatch RM, Walters L: The Nuremberg Code and the World Medical Association Declaration of Helsinki, in: Sourcebook in Bioethics: A Documentary History. Georgetown University Press, Washington, DC, 1998, pp 11-15
10. Von Staden H: In a pure and holy way: Personal and professional conduct in the Hippocratic Oath. J History Med Allied Sci 51:406-408, 1996
11. ABIM, ACP-ASIM, EFIM: Medical professionalism in the new millennium: A physician charter. Ann Intern Med 136:243-246, 2002
12. Pocock SJ: Statistical and ethical issues in monitoring clinical trials. Stat Med 12:1459-1469, 1993
13. Lilford RJ, Braunholtz D, Edwards S, et al: Monitoring of clinical trials: Interim data should be publically available. BMJ 323:441-442, 2001